J. W. Fay, A. K. Palucka, S. Paczesny, et al., “Long-Term Outcomes in Patients with Metastatic Melanoma Vaccinated with Melanoma Peptide-Pulsed CD34(+) Progenitor-Derived Dendritic Cells,” Cancer Immunology, Immunotherapy, Vol. 55, No. 10, 2006, pp. 1209-1218. doi:10.1007/s00262-005-0106-6

has been cited by the following article:

• TITLE: Clinical and Immunological Effects in Patients with Advanced Non-Small Cell Lung-Cancer after Vaccination with Dendritic Cells Exposed to an Allogeneic Tumor Cell Lysate

  AUTHORS: Lotte Engell-Noerregaard, Pia Kvistborg, Mai-Britt Zocca, Ayako W. Pedersen, Mogens H. Claesson, Anders Mellemgaard

  KEYWORDS: NSCLC; Dendritic Cells; Vaccination; Tumor Lysate

  JOURNAL NAME: World Journal of Vaccines, Vol.3 No.2, May 22, 2013

  ABSTRACT: Background: We evaluated the clinical and immunological effects of dendritic cell (DC) vaccination of patients with NSCLC. Autologous DCs were pulsed with a MAGE containing allogeneic melanoma cell lysate (MelCancerVac?, Dandrit Biotech,Copenhagen,Denmark). Imiquimod cream, proleukin and celecoxib were used as adjuvants to the vaccines. The objective of the study was to evaluate specific T cell response in vitro by IFNg EliSpot. Secondary objectives were overall survival, response and quality of life (QoL). Results: Twenty-two patients initiated the vaccination program consisting of ten vaccinations. Seven patients remained in stable disease (SD) three months after the first vaccination. After ten vaccinations (six months), four patients still showed SD and continued vaccinations on a monthly basis. These four patients received a total of 12, 16, 26 and 35 vaccinations, respectively. Five patients showed an unexpectedly prolonged survival. The treatment was well tolerated and only minor adverse events were reported. Quality of life did not change during the study period. In four of the seven patients with SD, vaccine-specific T cells were detected by IFNγ EliSpot assays, whereas only one patient with progressive disease (PD) showed vaccine-specific responses. Conclusion: This DC-based vaccine trial has indicated a correlation between vaccine-specific immunity and sustained SD. Furthermore, we observed an unexpectedly prolonged survival in some patients, which may indicate delayed effect of DC vaccination after completion of the treatment. A prospective randomized phase-IIb or -III is needed to further evaluate the use of MelCancerVac? vaccine treatment in patients with progressive NSCLC.